ACT
Optimal Timing of a tailored Physical Activity program during chemotherapeutic Cancer Treatment to reduce Long-term Cardiovascular Morbidity METc nr: 2012/260 Onderzoekscode: ON76 ClinicalTrials.gov registratie: NCT01642680 Samenvatting Het aantal...
CPCT-02
Development of a platform for next-generation DNA sequencing based personalized treatment for cancer patients: Protocol to obtain biopsies from patients with advanced (incurable) or metastatic cancer (CPCT –...
CTMX-M-072-001 (PROCLAIM-001)
An open-label, dose-finding and proof of concept study of the PD-L1 probody™ therapeutic, CX-072, as monotherapy and in combination with yervoy (ipilimumab) or with zelboraf (vemurafenib) in subjects...
G1T48
Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Ascending Doses of G1T48 in Women with Estrogen Receptor-Positive, HER2-Negative Advanced Breast...
M14DPD
Safety, feasibility and cost-effectiveness of genotype-directed individualized dosing of fluoropyrimidines. Protocolnummer: M14DPD EudraCT nummer: 2014-005064-15 METc nummer: 2016/081 Onderzoekscode: Samenvatting In deze studie zal onderzocht worden of het...
SMART
Self-monitoring and empowering physical activity with a SMARTphone application during or after cancer treatment in a 12 week follow-up: a randomized feasibility study. METc nummer: 2014/569 Samenvatting Een...